Abstract: Objective:To observe the clinical efficacy of Bairui particles as adjuvant therapy for children with mycoplasma pneumonia.Methods:Totally 100 children with mycoplasma pneumonia were randomly divided into an observation group(n=50) and a control group(n=50), according to the order of admission. In addition to convention therapy, erythromycin and azithromycin were also used for the control group, and Bairui particles together with the therapy for control group was used for the observation group. Compare the total effective rate, time of abatement of fever ,time for cough and lung rales to disappear and the occurrence of adverse reactions.Results：The total effective rate of the observation group was 94%, and the control group 80%;the difference had statistical significance(P<0.05). There was significantly difference(P<0.05) on time of fever abatement, cough and lung rales between observation group and control group. The incidence of adverse drug reactions in the two groups showed no significant difference(P>0.05).Conclusion：Bairui particles as adjuvant treatment for children with mycoplasma pneumonia can significantly promote the clinical efficacy and improve symptoms and signs, which is effective and safe and should be widely used in clinics.

Key words: Mycoplasma pneumoniae pneumonia, Bairui particles, Erythromycin, Azithromycin, Children